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Abstract
Background: Conditioning of physiological responses can be achieved by repeatedly pairing a previously neutral
conditioned stimulus with the administration of a pharmacologically salient unconditioned stimulus. This type of
conditioning has been effective for specific immune and endocrine responses, but results with regard to
conditioning of cortisol, a key stress-regulatory parameter, are currently unclear. This paper describes a
pharmacological conditioning design, optimized for the examination of effects of cortisol conditioning under both
basal conditions and in response to stress.
Methods: A double-blind randomized controlled conditioning paradigm aimed at conditioning of cortisol is
conducted in 48 healthy female volunteers. During the acquisition phase, a gustatory stimulus (conditioned
stimulus) is paired with hydrocortisone (100 mg, capsulated, unconditioned stimulus) three times before being
administered together with placebo during three evocation sessions. To investigate possible effects of cortisol
conditioning in response to stress, participants are exposed to the Trier Social Stress Test during the third evocation
session. Primary outcome measure of this study is the mean area under the curve of salivary cortisol during the first
two evocation sessions. As secondary outcomes, self-reported affect and stress as well as alpha-amylase are
investigated. A pilot study was conducted to ensure that this design is feasible to be used in a larger study.
Discussion: This study design provides an innovative opportunity to examine the conditioning of cortisol under
basal conditions and in response to stress. Also, the possible effect of cortisol conditioning on secondary outcomes
of self-reported affect and alpha-amylase can be investigated. If cortisol could successfully be conditioned, this
would be of conceptual relevance, showing that hypothalamic pituitary adrenal (HPA) axis regulation can be
influenced by associative learning processes. Eventually, this could also have important clinical implications for
understanding and treating stress-related disorders in which HPA axis dysregulation might play a role.
Trial registration: Nederlands Trial Register, NTR4651. Registered on 29 July 2014
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Background
Conditioning of physiological responses can be achieved by
repeatedly pairing a previously neutral stimulus (e.g., taste
or odor; conditioned stimulus, CS) with the administration
of a pharmacologically salient stimulus (e.g., an immuno-
modulatory agent; unconditioned stimulus, UCS). After
repeated pairing of CS and UCS, administration of the CS
alone or in combination with a placebo pill evokes a condi-
tioned response (CR), which can be either mimicking or
counter balancing the unconditioned response (UCR)
elicited by the pharmacological stimulus. This type of con-
ditioning is effective for conditioning immunosuppressive
[1–4], allergic [5, 6], and glycemic responses [7–9]. The
conditioned physiological responses observed in these stud-
ies are also called learned placebo effects, as the effective
qualities of the pharmacological stimulus (UCS) are trans-
ferred to a previously inert stimulus (CS), which is often ad-
ministered in combination with a placebo [10, 11].
Conceptually, they have important implications for the in-
vestigation of placebo effects, as they illustrate the close
interaction between the central nervous system (CNS) in
which the association between UCS and CS is thought to
be taking place and peripheral functions regulating the
UCR and, later, the CR [10]. In comparison to other
placebo-inducing mechanisms, such as verbal suggestion,
conditioning, and other learning mechanisms tend to in-
duce larger placebo effects that can be evoked repeatedly
[12]. Clinically, conditioned physiological responses may in
time be used to reduce the amount of medication needed
to ameliorate symptoms and thereby might also help
to reduce unwanted side effects. First studies in this
direction revealed promising results [13–18].
While conditioned immunosuppressive responses can
reliably be replicated [1–4], results regarding the endo-
crine parameter cortisol have been less consistent [19–
21], albeit not less relevant. Cortisol has been identified
as an important target for conditioning, as there is a
strong bi-directional communication between the CNS
and the adrenal glands that produce and release cortisol
via the hypothalamic pituitary adrenal (HPA) axis, which
is seen as a prerequisite for conditioning. Clinically, dys-
regulation of the key stress-regulatory parameter cortisol
is thought to be involved in a variety of stress-related
disorders [22–24] and blunted cortisol responses to
stressors are associated with the development and main-
tenance of autoimmune and chronic inflammatory dis-
eases [25–27]. Also, interventions targeting cortisol have
shown promising results including reduced negative
affect in response to a short-term psychosocial stress
task [28], reduced attentional bias toward angry faces in
social phobia [29], and reduced frequency and intensity
of intrusions in PTSD [30]. As the effects of interven-
tions targeting cortisol emerge predominantly under
stressful conditions, it would be of interest to investigate
conditioning of cortisol not only under basal conditions,
but also in response to stress. Successful conditioning of
cortisol might thus not only provide new insights into
the central regulation of the HPA axis, it might eventu-
ally also provide new ways to address dysregulation of
the HPA axis in clinical settings, where it may become a
valuable addition to existing treatment options for
stress-related disorders.
Cortisol conditioning has been addressed by several ani-
mal studies, providing indications that the equivalent to
cortisol in rodents, corticosterone, can be conditioned
[31–33]. In humans, however, only very few studies have
been conducted on this topic. One study has found condi-
tioned cortisol decreases after conditioning with sumatrip-
tan, which inhibits the release of cortisol [20]. However,
another study, in which the glucocorticoid dexametha-
sone, which inhibits the release of cortisol, was used as
UCS has led to inconclusive results, showing a statistically
significant interaction effect across groups (conditioned
vs. placebo control) and measurement (evocation vs. no
evocation), but post hoc tests remained statistically
non-significant [19]. A third study did not show significant
increases in cortisol and noradrenaline after conditioning
with corticotropin-releasing hormone, which stimulates
the release of adrenocorticotropic hormone and in turn
cortisol, although a post hoc analysis revealed that partici-
pants with above-median cortisol levels at baseline did
show significantly increased cortisol production as a con-
ditioned effect [21]. As the studies addressing condition-
ing of cortisol so far have all used different unconditioned
stimuli, which affect cortisol release in different directions
and possibly also via different regulatory mechanisms, it is
difficult to compare the obtained results. In general, these
studies provide indications that conditioning of cortisol
might be possible, without allowing a clear conclusion at
this time.
The current study design aims to build on previous
research, using hydrocortisone as UCS, and examining
conditioned responses not only under basal condi-
tions, but also in response to psychosocial stress.
Hydrocortisone was chosen as unconditioned stimulus
as it is the pharmacological equivalent of cortisol. In
the central nervous system, hydrocortisone binds to
mineralocorticoid as well as glucocorticoid receptors,
while dexamethasone, which was previously used to
condition cortisol [19], binds to glucocorticoid recep-
tors only. Also, previous studies using hydrocortisone
to manipulate cortisol levels showed promising results
with important implications for the treatment of
stress-related disorders [28–30]. Including a psycho-
social stress task in the design as a real-world chal-
lenge of the system in which the conditioned
response is to occur, provides the opportunity to
pre-test the possible clinical relevance of conditioning
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of the HPA axis in the future and to optimize the ex-
ternal validity of the study.
A double-blind, randomized, placebo-controlled study
design is proposed, in which hydrocortisone (UCS) is re-
peatedly paired with a gustatory conditioned stimulus.
As primary outcome, this study examines effects of con-
ditioning on salivary cortisol under basal conditions.
Secondary outcomes are cortisol in response to stress
and self-reported affect, stress, and alpha-amylase both
under basal conditions and in response to stress. Add-
itionally, parameters indicating autonomic responses to
stress (heart rate and skin conductance) are explored.
The present paper describes the design of this study, in-
cluding a small pilot study conducted to test its feasibil-
ity (see also [34]).
Methods
The study protocol has been approved by the medical
research ethics committee of the Leiden University Med-
ical Center (LUMC; P14-020, NL47105.058.14). The
study is conducted according to the principles of the
Declaration of Helsinki (21.10.2008) and in accordance
with the Dutch Medical Research Involving Human Sub-
jects Act (WMO). The Standard Protocol Items: Recom-
mendations for Interventional Trials 2013 (SPIRIT)
Checklist is presented as Additional file 1. All data (e.g.,
questionnaires, laboratory results) are stored using an-
onymous participant identification codes and will be
kept for a period of 15 years. The file linking the partici-
pant identification codes and personal data is managed
by the researchers and the data manager, and is locked
for access by others. In accordance with the Central
Committee on Research Involving Human Subjects
statement on publication policy, the results of this study
will be submitted for publication in peer-reviewed jour-
nals, regardless of confirmation or disconfirmation of
the hypotheses.
Study participants
In view of the higher prevalence of stress-related disor-
ders in women than men [35], this study is conducted
in female participants. To be eligible, participants need
to be between 18 and 30 years of age, premenopausal,
and capable of understanding and producing Dutch flu-
ently. Potential participants are excluded if they have
psychiatric (Diagnostic and Statistical Manual of Men-
tal Disorders-IV, DSM-IV) conditions, are diagnosed
with a somatic disease that might interfere with the
participant’s safety and/or the study protocol, use medi-
cation including oral contraceptives or any kind of
drugs, have recently experienced stressful life events,
are or intend to become pregnant at the time of partici-
pation or engage in breast feeding, or suffer from a
known hypersensitivity or allergy to one of the
ingredients of the hydrocortisone and placebo capsule
or the gustatory conditioned stimulus used in the study.
Eligibility of potential participants is assessed during a
screening appointment.
Study design
Experimental phases
The design proposed for this study (see Fig. 1) is based on a
widely used double-blind, randomized, placebo-controlled
conditioning paradigm, consisting of two phases (e.g., [2, 4,
9]). The first phase is the acquisition phase (session 1 to 3),
in which an association between the pharmacologically sali-
ent unconditioned stimulus (UCS) and the previously neu-
tral conditioned stimulus (CS) is established by repeated
paired administration. In the second phase, the evocation
phase (session 4 to 6), it is tested whether administration of
the CS with an identically-looking placebo pill elicits a con-
ditioned response. In the current study, participants are
additionally exposed to a psychosocial stress task during
the final evocation session (session 6), in order to investi-
gate whether conditioning affects the psychophysiological
response to stress.
Conditioned stimulus (CS)
The CS used in this study is 150ml of a distinctively tast-
ing green beverage. The beverage consists of strawberry
milk (Campina b.v., the Netherlands) to which yellow (chi-
nolin yellow, Caelo, Germany) and blue (patent blue,
Caelo, Germany) colorant, and lavender oil (KeyPharm
Laboratories, Belgium) is added to achieve the green color
and distinctive flavor. This beverage has previously been
used as conditioned stimulus in several studies addressing
conditioned immune responses [1–4, 15, 16, 36, 37].
Unconditioned stimulus (UCS)
The UCS used in this study is 100 mg of hydrocortisone.
The dosage of 100mg is chosen as it leads to a pro-
nounced increase of cortisol without causing subjectively
noticeable effects [38, 39]. Also, repeated administration
of this dosage is unlikely to cause any unwanted side ef-
fects in healthy participants [40].
Randomization and blinding
This experiment is conducted in a double blind manner.
Randomization and blinding as well as production of
identically looking hydrocortisone and placebo pills is
done by the Pharmacy of the Leiden University Medical
Center. Pills are delivered in two containers, one for the
acquisition and one for the evocation phase. Each con-
tainer contains three pills, one for each day of the ex-
periment. Containers are labeled with the participant
and study code and the study phase in which the pills
should be administered (week 1 for acquisition, week 2
for evocation). To check for blinding, at the end of the
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study, participants are asked whether they thought to
have received hydrocortisone or placebo during each
session of the experiment.
Measurements and materials
Salivary cortisol and alpha-amylase
Cortisol and alpha-amylase are assessed under basal
conditions and as markers of the psychophysiological re-
sponse to stress by means of saliva samples [41, 42] col-
lected with salivettes (Sarstedt, Rommelsdorf, Germany).
Participants will be instructed to place the cotton swab
contained in the salivette tube in their mouth and move
it through their mouth using their tongue for 1 min.
Participants are specifically instructed not to bite or
chew on the cotton swab and not to touch it with their
hands. Especially for stress-related research, the advan-
tage of salivary measures compared to blood sampling is
that the collection of saliva is non-invasive, inducing no
or minimal amounts of stress [42]. Saliva samples are
stored at − 80 °C at the Biobank in the LUMC.
Heart rate and skin conductance
Heart rate and skin conductance level are assessed as a
measure of autonomic activity, using a non-invasive Bio-
pac© apparatus consisting of the MP150 Data Acquisi-
tion System and the ECG100C Electrocardiogram
Amplifier and the GSR100C module with a sampling
rate of 1000 per second. For heart rate recordings,
electrodes are applied to the participants’ body employ-
ing a Lead-II configuration (one on the chest, one on
the ribs; no ground is needed because of the simultan-
eous recording of skin conductance) and a high-pass fil-
ter of 0.5 Hz is used. For skin conductance, two
electrodes are being applied to the skin of the partici-
pants’ non-dominant hand. Gain is set to 5 μƱ/V, and a
low-pass filter of 10 Hz is used.
Self-reported positive and negative affect
State positive and negative affect is assessed using the
Dutch state version of the Positive and Negative Affect
Schedule (PANAS, [43]). This validated and widely used
self-report questionnaire asks for the level at which the
participant experiences 10 negative emotion adjectives
and 10 positive emotion adjectives at this moment, to be
answered on a 5-point Likert scale (1 = “very slightly or
not at all,” 5 = “extremely”) and takes about 2 min to
complete.
Self-reported stress
Visual analog scales (VAS, [44]) are used to additionally
measure stress-related items. The VAS were previously
used by Childs et al. [45] and de Brouwer et al. [46] to
assess seven psychological states at this moment (e.g., re-
laxed, nervous), anchored from “not at all,” reflecting a
score of 0, to “very much so,” reflecting a score of 100.
Fig. 1 Overview of the study design. After screening, participants are randomized to either the hydrocortisone conditioning group or the placebo
control group. Each group undergoes six experimental sessions. During the acquisition phase (week 1), the hydrocortisone conditioning
group is administered a capsule containing 100mg of hydrocortisone (unconditioned stimulus, UCS) combined with a distinctively tasting
beverage (conditioned stimulus, CS), whereas the placebo control group receives an identically looking placebo capsule and the same beverage.
During the evocation phase (week 2), all participants receive a placebo capsule and the beverage. In the final session, all participants are
exposed to a psychosocial stress task
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Psychosocial stress task
The psychosocial stress task administered during the
final evocation session (session 6) is the Trier Social
Stress Test (TSST, [47]). Consisting of a 5-min prepar-
ation period, a 6-min prepared free speech, and a 4-min
mental arithmetic task, the TSST has been shown to re-
liably elicit psychophysiological responses, including ele-
vated cortisol and sympathetic activation [48, 49].
Procedure
Recruitment and consent
Participants are recruited from the student population of
Leiden University by means of printed and digital adver-
tisements. When a person indicates interest in partici-
pating, she is provided with information about the study
in writing and all appointments for the study are sched-
uled via telephone. During the first appointment, partici-
pants are informed about the study orally, invited to ask
any additional questions, and asked to provide written
informed consent to the experimenter. To rule out pos-
sible conscious expectancy effects of knowing about the
conditioning procedure, all participants are told that the
purpose of the experiment is to investigate the effects of
repeated administration of hydrocortisone. No details
about possible effects of hydrocortisone administration
are given, except for the standardized information leaflet
of hydrocortisone that is provided to participants as part
of the standard informed consent procedure. All partici-
pants are informed that they can end their participation
at any time during the study, without the need to pro-
vide a reason and without any negative consequences.
Also, they are informed that the investigator could po-
tentially decide to exclude them from further participa-
tion in the study for safety reasons. Might they occur, all
adverse events are followed up until they have abated or
until a stable situation has been reached. Depending
on the event, follow-up may require referral to the
general physician or a medical specialist. Possible
damage to research subjects through injury or death
caused by the study is covered by an insurance that
is in accordance with the legal requirements in the
Netherlands (Article 7 WMO and the Measure re-
garding Compulsory Insurance for Clinical Research
in Humans of 23 June 2003).
Screening
Before entering the experiment, subjects who indicate
interest to participate in the study are screened with ques-
tionnaires and a structured interview for the presence of
any psychiatric (DSM-IV) condition [50] at the Faculty of
Social and Behavioural Sciences of Leiden University. In
addition, potential participants are screened for all somatic
diseases that might interfere with the participant’s safety
and/or the study protocol by a physician at the LUMC. In
the 24 h before a study appointment, subjects are asked to
refrain from drinking alcoholic beverages and using drugs.
They are also instructed not to engage in physical exercise
during the 12 h before an appointment. For the 2 h before
an appointment, participants are asked not to eat heavy
meals, drink caffeinated beverages, including tea, or to
smoke cigarettes. During the screening, demographic
characteristics of the participants and variables known to
affect cortisol levels (such as menstrual cycle phase, BMI,
smoking and perceived stress) are assessed using
self-report questionnaires (e.g., Perceived Stress Scale,
PSS, [51]). Subsequently, baseline measurements of
self-reported affect and stress, saliva collection for meas-
urement of cortisol and alpha-amylase and recordings of
heart rate and skin conductance commence. If subjects
are eligible to participate, they enter the randomization
scheme.
Acquisition phase
Each of the three acquisition sessions follows the same
regimen. Upon arrival at the laboratory at the Faculty of
Social and Behavioural Sciences of Leiden University,
the participant is asked to complete a self-report ques-
tionnaire measuring affect and seven VAS measuring
stress. Then, a saliva sample for cortisol and alpha-
amylase is taken. Next, participants are administered a
pill containing either 100 mg of hydrocortisone or pla-
cebo paired with the gustatory CS. Subsequently, the
participant is instructed to avoid potential activities that
might interfere with conditioning for the next 4 h (e.g.,
drinking caffeinated or alcoholic beverages, consuming
heavy meals, and exercising).
Evocation phase
A week after the acquisition phase, the three evocation
sessions take place (on the same days of the week as the
acquisition sessions). As shown in Fig. 2, each of the
three evocation sessions follow the same regimen. First,
participants are provided with electrodes to record heart
rate and skin conductance throughout the session. Next,
participants are asked to complete the self-report ques-
tionnaires on affect and stress again. Also, a saliva sam-
ple for cortisol and alpha-amylase measurement is taken
and the participant is asked to sit still for a 5 min re-
cording of heart rate and skin conductance (T-10). After
this baseline measurement, participants are administered
a placebo pill paired with the same distinctively tasting
beverage as used in the acquisition sessions (T0).
Self-report measurements of affect and stress, saliva col-
lection, and heart rate and skin conductance recordings
are repeated with intervals of 30min (T + 30–T + 120). In
evocation sessions 4 and 5, measurements are conducted
5 times, and in session 6 an extra measurement takes
place 30min after the fifth measurement. In the time
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between measurements, participants are asked to
complete several undemanding and non-stressful filler
tasks. In session 6, participants are additionally presented
with the TSST.
Debriefing
After the last evocation session, participants are
debriefed about the conditioning procedure. If partici-
pants choose to withdraw before completion of the
study, they are debriefed as soon as their decision to
withdraw is final. All participants will be informed about
their group allocation and the study results when the
study is finalized.
Statistical analysis
Main outcome parameter of this study is the area under
the curve from ground (AUCg) of all salivary cortisol
measurements in sessions 4 and 5, thus evocation under
basal conditions. Data will be analyzed by an ANCOVA
with condition (hydrocortisone or placebo) as independ-
ent variable and AUCg of salivary cortisol as dependent
variable. As the AUCg of salivary cortisol from our pilot
study showed a strong correlation with perceived stress
(score on PSS during screening), PSS score and other
potentially relevant covariates will be added to the
analysis.
Secondary outcome parameters are AUCg of salivary
cortisol in session 6 and alpha-amylase, self-reported
affect, and stress for which separate analyses will be con-
ducted for measurements under basal conditions (ses-
sions 4 and 5) and in response to stress (session 6).
Additionally, effects of conditioning on the autonomic
parameters heart rate and skin conductance will be ex-
plored. These analyses will be similar to those described
for the primary outcome measure.
Sample size
In order to gain insight into the effect size of the group
difference in basal cortisol after conditioning (primary
outcome measures) that could be expected when condi-
tioning with hydrocortisone, a pilot study was conducted
using a similar design as in the current study. This pilot
study in 10 female participants (7 receiving hydrocorti-
sone in the acquisition phase and 3 receiving placebo)
found a difference (Δm) in the AUCg of cortisol during
the first 2 evocation sessions of 6.14 with a weighted
standard deviation of 11.68, resulting in an effect size of
d = 0.53. Because of the preliminary character of this
pilot study, findings of comparable studies on the effects
of conditioning on endocrine outcomes (insulin, blood
glucose; [7–9]) were also taken into account. In these
comparable studies, effect sizes of d = 0.73 [9], d = 0.57
([7]; insulin vs. placebo control group), and d = 0.77 [8]
were found. Resultantly, we ran the power analysis with
an averaged and conservatively rounded effect size of
d = 0.60. Because a high correlation between the out-
come variable AUCg of cortisol under basal conditions
and the subjectively perceived stress level (PSS) at base-
line (r = .85) was found in our pilot study, a conservative
estimate of this correlation (r = .70) was added as a de-
sign factor in the sample size calculation [52]. Based on
these estimations, a sample size calculation for an inde-
pendent samples t test indicated that with an alpha level
of 0.05 and a power of 0.80, 46 participants would be
needed. Due to block randomization, the total number
of participants to be included was adjusted to 48.
Pilot study
A pilot study was conducted in 10 healthy female
volunteers at the Radboud university medical center
(Radboudumc) to gain information about the feasibility
Fig. 2 Measurement schedule for the evocation sessions: each of the evocation sessions has the same time schedule, with exception of the sixth
session in which one filler task is replaced by the Trier Social Stress Test, and a sixth measurement is added at T + 150
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of the design, next to providing input for the potential ef-
fect size of the conditioned effect as described in the pre-
vious paragraph. The pilot study was ethically approved
by the medical research ethics committee of the Radbou-
dumc (2012/290, NL40509.091.12). Because basal cortisol
(e.g., [53, 54]) and cortisol responses to the TSST without
conditioning have already been investigated in previous
research (e.g., [48, 49]), an unequal group allocation was
chosen, with more participants being allocated to the
hydrocortisone conditioning group (n = 7) than to the pla-
cebo control group (n = 3). Regarding the usefulness and
practicality of the measurement schedule used in this
study, the absence of missing values in any of the physio-
logical assessments (cortisol, alpha-amylase, heart rate,
and skin conductance) or self-report affect questionnaire
(PANAS) indicates that the number and frequency of
measurement points in this study was feasible. The check
for blinding conducted at the end of the study indicated
that none of the participants was able to guess reliably
whether she had received hydrocortisone or placebo at
any point of the study. None of the participants reported
physical symptoms that could be attributed to the hydro-
cortisone treatment during the study.
While the design of the pilot study was the same as the
design of the current study, some adaptations have been
made in the study procedure. In the pilot study, the pro-
cedure of the acquisition sessions (session 1 through 3)
was identical to the evocation sessions (sessions 4 and 5)
as depicted in Fig. 2. Thus, each session comprised 5
measurement points, 1 every 30min, and lasted approxi-
mately 2.5 h. The pilot data showed that administration of
100mg hydrocortisone in the hydrocortisone conditioning
group induced mean increases of 1237.66mmol/l (sd =
485.45) from baseline in salivary cortisol within 120min
(measurements taken every 30min), while none of the
participants reported any subjectively noticeable (side-)ef-
fects of the hydrocortisone treatment. No changes in saliv-
ary cortisol were indicated in the placebo control group
(mean difference from baseline − 2.28mmol/l; sd = 1.12).
Also, no changes in self-reported affect (PANAS) and
alpha-amylase were indicated in both groups during the
acquisition phase. Therefore, the acquisition sessions of
the current study were limited to a baseline measurement
of salivary cortisol and the standardized administration of
CS and UCS, in order to significantly reduce participant
burden.
Discussion
To investigate conditioned responses of the hypothal-
amic pituitary adrenal (HPA) axis parameter cortisol,
both under basal conditions and in response to psycho-
social stress, a double-blind, randomized study design is
proposed. The current study design aims to build on
previous research, by investigating possible conditioned
responses under basal conditions as well as in response
to psychosocial stress, providing the opportunity to
pre-test the possible clinical relevance of conditioning of
the HPA axis in the future and to optimize the external
validity of the study. Therefore, effects of conditioning
on alpha-amylase, self-reported affect, and stress are
assessed as well.
The design used in this study is based on previous studies
in which immune and glycemic responses were classically
conditioned (e.g., [2, 4, 9]). The conditioned stimulus (CS)
used in this study is a distinctively tasting beverage also
used in previous conditioning studies [1–4, 15, 16, 36, 37],
providing a gustatory stimulus that is unfamiliar to partici-
pants and has therefore not been associated with other
stimuli prior to this experiment. Unlike in previous studies
on the conditioning of cortisol, hydrocortisone was chosen
as the unconditioned stimulus (UCS) in this study. In our
pilot study, administration of hydrocortisone during the ac-
quisition phase led to a marked increase in salivary cortisol,
while blinding of the participants and experimenters was
not compromised, supporting its potential usefulness as
UCS for conditioning cortisol. The number of acquisition
and evocation sessions was also based on previous studies.
Studies in humans have used between one [5, 6] and six [8]
repetitions of paired administrations of the CS and UCS.
Classical conditioning theory and preliminary data suggest
that more paired administrations of CS and UCS during ac-
quisition more reliably lead to conditioned responses [5].
This finding is reflected in the choice for three paired
administrations of CS and UCS in this study, using
multiple acquisitions while ensuring practical feasibility
of the study and minimizing the burden for partici-
pants. In previous studies, time laps between the paired
administrations varied between several minutes [8] to 1
or 2 weeks [19]. In the current study, considering the
8-h half-life of hydrocortisone, paired administrations
of CS and UCS could only take place once per day in
order to prevent a build-up of hydrocortisone in the
participants. To keep paired administrations together
as closely as possible, the acquisition sessions in this
experiment take place on three consecutive days. After
the acquisition phase and before the evocation phase,
there is a drug washout period of 4 days to ensure mea-
surements in the evocation phase are not influenced by
residues of hydrocortisone or suppression of the HPA
axis that might result from hydrocortisone treatment.
As previous studies have shown that not all conditioned
effects are evident after the first evocation [36], this
study design includes three evocation sessions. To
optimize conditioned effects in case stimuli other than
the beverage have also become associated with the
UCS, the procedure surrounding the administration of
CS and UCS during these sessions as well as the lab en-
vironment and the experimenter are the same during
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acquisition and evocation sessions for each participant.
This highly repetitive nature of the study procedures
has the additional advantage that all events occurring
during the study appointments (with exception of the
TSST in the last session) are highly predictable for the
participants, and thereby minimizes effects of novelty
or anticipation. To investigate conditioned responses in
reaction to stress, participants are exposed to the Trier
Social Stress Test (TSST) during the last evocation ses-
sion. Cortisol is a key-stress regulatory parameter and
its dysregulation is thought to be involved in a variety
of stress-related disorders [22–24]. Therefore, in this
study, conditioned responses are investigated not only
under basal conditions but also in response to psycho-
social stress which provides the opportunity to pre-test
the possible clinical relevance of conditioning of the
HPA axis in the future and to optimize the external val-
idity of the study. Regarding the feasibility of the overall
design used in this study, the results of the pilot study
have demonstrated that this design is feasible to be
used in a larger study. No participants reported side ef-
fects of hydrocortisone treatment and only three partic-
ipants dropped out, all with reasons unrelated to the
study protocol. Finally, a power analysis based on find-
ings from the pilot study as well as previous studies in-
dicated a number of 48 participants to be included in
this study, making this the largest study on condition-
ing of the HPA axis conducted thus far.
This study includes only healthy female volunteers
with a limited age range. This benefits the homogeneity
of the sample and therefore increases chances of finding
reliable effects. Also, women show a higher prevalence
of stress-related disorders than men [35] and are, there-
fore, a more relevant group to target for this study.
Menstrual cycle phase, a factor known to affect cortisol
responses to stress, is noted, but the experimental ses-
sions are not scheduled in a specific phase of the men-
strual cycle. Furthermore, all measurements in this study
are non-invasive. More invasive procedures such as
blood sampling is known to cause stress in most individ-
uals and could thereby possibly trigger responses of the
HPA axis [53], which might confound the results and
possibly disrupt the conditioning process.
If cortisol could successfully be conditioned, this
would be of conceptual relevance, showing that hypo-
thalamic pituitary adrenal axis regulation can be influ-
enced by associative learning processes. It would also
provide opportunities for future research and clinical ap-
plications. As cortisol is a key stress-regulatory param-
eter and HPA axis dysregulation might play a role in
stress-related disorders, cortisol conditioning could be
investigated experimentally in patient populations, pos-
sibly using a stress-inducing challenge relevant and ap-
propriate for the specific group (e.g., exposure to a
phobic stimulus). Not only could this provide further
insight into mechanisms underlying stress-related disor-
ders, it may also identify cortisol conditioning as a valu-
able addition to existing cognitive-behavioral treatments
of stress-related disorders.
To conclude, the proposed study design aims to pro-
vide more clarity on the possibility to condition HPA
axis responses in humans and expands previous studies
by investigating possible conditioned responses under
basal conditions as well as in response to psychosocial
stress. Results from our pilot study have already demon-
strated that this design is feasible, providing sufficient
ground to examine this design further in a larger ran-
domized controlled trial (see also [34]). If cortisol could
successfully be conditioned, this would be of conceptual
relevance, showing that HPA axis regulation can be in-
fluenced by associative learning processes. Eventually,
this could also have important clinical implications for
understanding and treating stress-related disorders in
which HPA axis dysregulation might play a role.
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